# Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

> **NCT01778049** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 708 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773
- **DRUG:** BI 10773 Placebo
- **DRUG:** BI 10773 / BI 1356
- **DRUG:** BI 10773
- **DRUG:** BI 10773 / BI 1356
- **DRUG:** BI 10773 / BI 1356 Placebo
- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** BI 10773 / BI 1356 Placebo
- **DRUG:** BI 10773 Placebo
- **DRUG:** BI 10773 / BI 1356 Placebo
- **DRUG:** BI 10773
- **DRUG:** BI 10773 / BI 1356 Placebo

## Key facts

- **NCT ID:** NCT01778049
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 708 (ACTUAL)
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01778049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01778049, "Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01778049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*